---

Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡

---

Bayer

🌎 bayer.com

Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. The company focuses on advancing health and nutrition, addressing challenges posed by a growing and aging global population. Bayer is committed to sustainable development and aims to generate a positive impact through its products and services, which include pharmaceuticals, consumer health, crop science, and life sciences.

---

Bayer - Latest News and Updates

• On November 13, 2024, Bayer CropScience Limited reported Q2 FY 2024-25 revenue of ₹17,376 million and a profit before tax of ₹1,901 million, declaring an interim dividend of ₹90 per share.
• Bayer reports strong Q3 2024 performance in Pharmaceuticals and Consumer Health, but faces challenges in Crop Science and regulatory issues.
• Bayer's shares dropped 11.6% to a 20-year low after forecasting further earnings decline in 2025 due to weak agricultural markets, increasing pressure on CEO Anderson to improve performance.
• Bayer Thai received the AMCHAM Corporate Social Impact Award 2024 for the sixth consecutive year, recognizing its commitment to sustainable business practices.
• Bayer is currently hiring a Principal BizDevOps Lead in the United States.

• Carsten Dauster has left Bayer, where he served as VP Nutrient Efficiency and Crop Enhancement in the Greater Dusseldorf Area, to join UPL as Managing Director / Geschäftsführer UPL Deutschland GmbH.
• Bayer is currently hiring for the position of Director, Integrated Strategic Communications - US Pharmaceuticals in the United States.
• Bayer is currently hiring for the position of Public Market & Government Business Lead in India.
• Bayer reported a net loss of 4.18 billion euros in the third quarter, with a 3.6% revenue drop in its agricultural unit amid ongoing Roundup cancer lawsuits.
• Bayer's prostate cancer drug Nubeqa achieved blockbuster status with a 1.08 billion euro revenue, while Xarelto sales continue to decline due to generic competition.

---

Sign up to receive regular updates

If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.